Renaissance Technologies LLC Makes New $1.15 Million Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Renaissance Technologies LLC acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 98,700 shares of the company’s stock, valued at approximately $1,151,000.

Several other institutional investors have also recently made changes to their positions in NTLA. ARK Investment Management LLC lifted its holdings in shares of Intellia Therapeutics by 2.3% in the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock valued at $146,174,000 after buying an additional 280,946 shares during the period. Vanguard Group Inc. boosted its position in Intellia Therapeutics by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock worth $118,816,000 after purchasing an additional 562,249 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $43,177,000. Geode Capital Management LLC increased its holdings in shares of Intellia Therapeutics by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company’s stock valued at $27,865,000 after purchasing an additional 45,930 shares in the last quarter. Finally, Contrarius Group Holdings Ltd acquired a new position in shares of Intellia Therapeutics in the 4th quarter valued at $11,798,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $8.20 on Wednesday. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $28.18. The stock has a market cap of $848.84 million, a PE ratio of -1.51 and a beta of 2.23. The stock has a 50 day moving average price of $8.51 and a 200 day moving average price of $11.68.

Analyst Ratings Changes

NTLA has been the topic of several analyst reports. Wells Fargo & Company dropped their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Wedbush restated a “neutral” rating and set a $10.00 target price (down from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. BMO Capital Markets reduced their price target on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, January 10th. Barclays dropped their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Finally, Morgan Stanley downgraded Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $36.68.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.